Table 1. The basic characteristics of the 11 studies included.
| Study | Year | Country | Case number | FIGO stage | Age | Cut-off | Follow-up time | Category | Adjusted† | Survival analysis |
|---|---|---|---|---|---|---|---|---|---|---|
| Cozzi et al. [20] | 2016 | USA | 304 | I–IV | 59.9±14.8 | >350 | Unclear | Ovarian cancer | Yes | OS |
| 59.1±14.8 | >400 | |||||||||
| 59.8±14.8 | >450 | |||||||||
| Feng et al. [21] | 2016 | China | 875 | I–IV | 56 (30–90)* | >450 | 29 (1–115) | High-grade serous ovarian cancer | No | OS, PFS |
| Matsuo et al. [22] | 2015 | USA | 1,308 | I–IV | Unclear | >400 | 31.3 | Epithelial ovarian cancer | Yes | OS, PFS |
| Chen et al. [23] | 2015 | China | 816 | I–IV | 53 (21–79)* | >400 | 65 (0–140) | Epithelial ovarian cancer | Yes | OS, PFS |
| Man et al. [24] | 2015 | China | 190 | I–IV | 66 (27–90)* | >300 | 48 (2–150) | Epithelial ovarian cancer | Yes | OS, PFS |
| Digklia and Voutsadakis [25] | 2014 | Canada | 91 | III–IV | Unclear | >350 | 32.5 (1–140) | Serous ovarian cancer | Yes | OS, PFS |
| Allensworth et al. [26] | 2013 | USA | 578 | I–IV | Unclear | >450 | 35 (9–59) | Epithelial ovarian cancer | Yes | OS, PFS |
| Qiu et al. [27] | 2012 | China | 136 | I–IV | Unclear | >400 | Unclear | Epithelial ovarian cancer | Yes | OS, PFS |
| Lee et al. [28] | 2011 | Korea | 179 | III–IV | 54.3±11.1, 55.3±11.2 | >400 | Unclear | Advanced epithelial ovarian cancer | Yes | OS |
| Gungor et al. [29] | 2017 | Turkey | 293 | I–IV | 57.4±3.8, 58.2±2.9 | >400 | Unclear | Epithelial ovarian cancer | Yes | OS |
| Li et al. [15] | 2004 | USA | 183 | III–IV | 59.8 | >400 | Unclear | Advanced epithelial ovarian cancer | Yes | OS, PFS |
| 59.0 |
FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; PFS, progression-free survival.
*Median (range); †Adjusted: data from multivariate analysis with Cox proportional hazards regression model.